General information about company		
Scrip code*		506235
NSE Symbol*		ALEMBICLTD
MSEI Symbol*		NOTLISTED
ISIN*		INE426A01027
Name of company		Alembic limited
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2026
Date of end of financial year		31-03-2027
Date of board meeting when results were approved		06-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		28-10-2026
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Second quarter
Nature of report standalone or consolidated		Standalone
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Unaudited
Segment Reporting		Multi segment
Description of single segment		
Start date and time of board meeting		06-11-2026 16:00
End date and time of board meeting		06-11-2026 16:30
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Not applicable
Whether the company has any related party?		Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public		NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		07-02-2025
Indicate Company website link for updated RPT policy of the Company		https://alembiclimited.com/policy/Related-Party-Transaction-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		No
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Not Applicable

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
	Date of start of reporting period	01-07-2026	01-04-2026	
	Date of end of reporting period	30-09-2026	30-09-2026	
	Whether results are audited or unaudited	Unaudited	Unaudited	
	Nature of report standalone or consolidated	Standalone	Standalone	
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**			
1	**Income**			
	Revenue from operations	2768.67	7395.21	
	Other income	7161.99	7717.02	
	Total income	**9930.66**	**15112.23**	
2	**Expenses**			
(a)	Cost of materials consumed	293.05	785.91	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-217.57	-269.06	
(d)	Employee benefit expense	1131.78	2177.87	
(e)	Finance costs	32.91	70.37	
(f)	Depreciation, depletion and amortisation expense	346.34	684.49	
(g)	**Other Expenses**			
1	Cost of Construction	390.71	1252.84	
2	Other Expenses	749.2	1622.78	
	Total other expenses	**1139.91**	**2875.62**	
	Total expenses	**2726.42**	**6325.2**	
3	**Total profit before exceptional items and tax**	**7204.24**	**8787.03**	
4	Exceptional items	0	0	
5	**Total profit before tax**	**7204.24**	**8787.03**	
6	**Tax expense**			
7	Current tax	802.94	962.37	
8	Deferred tax	-300.33	-344.27	
9	**Total tax expenses**	**502.61**	**618.1**	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	**Net Profit Loss for the period from continuing operations**	**6701.63**	**8168.93**	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	**Total profit (loss) for period**	**6701.63**	**8168.93**	
17	Other comprehensive income net of taxes	6949.63	13255.87	
18	**Total Comprehensive Income for the period**	**13651.26**	**21424.8**	
19	**Total profit or loss, attributable to**			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	**Total Comprehensive income for the period attributable to**			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	**Details of equity share capital**			
	Paid-up equity share capital	5135.64	5135.64	
	Face value of equity share capital	2	2	
22	Reserves excluding revaluation reserve			
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	2.61	3.18	
	Diluted earnings (loss) per share from continuing operations	2.61	3.18	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	2.61	3.18	
	Diluted earnings (loss) per share from continuing and discontinued operations	2.61	3.18	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Text Block	
Textual Information(4)	1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. 2. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. 3. Figures rounded off to the nearest decimal.

Statement of Asset and Liabilities

	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	**Non-current assets**	
	Property, plant and equipment	16934.9
	Capital work-in-progress	150.99
	Investment property	30116.45
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	41121.88
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	
1	Other non-current financial assets	347.58
2		
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	**347.58**
	Total non-current financial assets	**41469.46**
	Deferred tax assets (net)	0
	Other non-current assets	
1	Other non-current assets	3500
2		
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	**3500**
	Total non-current assets	**92171.8**
2	**Current assets**	
	Inventories	5283.82
	Current financial asset	
	Current investments	10640.76
	Trade receivables, current	1292.77
	Cash and cash equivalents	117.27
	Bank balance other than cash and cash equivalents	235.36
	Loans, current	0
	Other current financial assets	
1	Other current financial assets	313.04
2		
3		
4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	**313.04**
	Total current financial assets	**12599.2**
	Current tax assets (net)	0
	Other current assets	
1	Other current assets	795.73
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	**795.73**
	Total current assets	**18678.75**
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	**110850.55**
	Equity and liabilities	

1	**Equity**	
	Equity attributable to owners of parent	
	Equity share capital	5135.64
	Other equity	92272.04
	Total equity attributable to owners of parent	**97407.68**
	Non controlling interest	
	Total equity	**97407.68**
2	**Liabilities**	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	0
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	**0**
	Other non-current financial liabilities	
1	Other non-current financial liabilities	1006.27
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	**1006.27**
	Total non-current financial liabilities	**1006.27**
	Provisions, non-current	549.64
	Deferred tax liabilities (net)	3176
	Deferred government grants, Non-current	0
	Other non-current liabilities	
1		
2		
3		
4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	**4731.91**
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	0
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	553.7
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1534.48
	Total Trade payable	**2088.18**
	Other current financial liabilities	
1	Other current financial liabilities	922.99
2		
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	**922.99**
	Total current financial liabilities	**3011.17**
	Other current liabilities	
1	Other current liabilities	2880.19
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	**2880.19**
	Provisions, current	2226.16
	Current tax liabilities (Net)	593.44
	Deferred government grants, Current	0
	Total current liabilities	**8710.96**
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	**13442.87**
	Total equity and liabilities	**110850.55**
	Disclosure of notes on assets and liabilities	

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results			
	Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-07-2026	01-04-2026
	Date of end of reporting period	30-09-2026	30-09-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
1	**Segment Revenue (Income)**		
	(net sale/income from each segment should be disclosed)		
1	Active Pharmaceutical Ingredients Business	679.31	1850.61
2	Real Estate Business	2089.36	5544.6
	Total Segment Revenue	2768.67	7395.21
	Less: Inter segment revenue	0	0
	Revenue from operations	2768.67	7395.21
2	**Segment Result**		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	Active Pharmaceutical Ingredients Business	-16.84	148.71
2	Real Estate Business	375.92	1600.37
	Total Profit before tax	359.08	1749.08
	i. Finance cost	32.91	70.37
	ii. Other Unallocable Expenditure net off Unallocable income	-6878.06	-7108.31
	Profit before tax	7204.23	8787.02
3	**(Segment Asset - Segment Liabilities)**		
	Segment Asset		
1	Active Pharmaceutical Ingredients Business	18569.07	18569.07
2	Real Estate Business	51159.58	51159.58
	Total Segment Asset	69728.65	69728.65
	Un-allocable Assets	41121.89	41121.89
	Net Segment Asset	110850.54	110850.54
4	**Segment Liabilities**		
	Segment Liabilities		
1	Active Pharmaceutical Ingredients Business	3827.02	3827.02
2	Real Estate Business	5846.41	5846.41
	Total Segment Liabilities	9673.43	9673.43
	Un-allocable Liabilities	3769.44	3769.44
	Net Segment Liabilities	13442.87	13442.87
	Disclosure of notes on segments		

Other Comprehensive Income			
	Date of start of reporting period	01-07-2026	01-04-2026
	Date of end of reporting period	30-09-2026	30-09-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Amount of items that will not be reclassified to profit and loss	7773.29	14835.27
	Total Amount of items that will not be reclassified to profit and loss	7773.29	14835.27
2	Income tax relating to items that will not be reclassified to profit or loss	823.66	1579.40
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	6949.63	13255.87

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026
	Date of end of reporting period	30-09-2026
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	8787.03
2	**Adjustments for reconcile profit (loss)**	
	Adjustments for finance costs	70.37
	Adjustments for decrease (increase) in inventories	-59.71
	Adjustments for decrease (increase) in trade receivables, current	1728.07
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	88.62
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	148.93
	Adjustments for other financial assets, current	40
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-207.96
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	42.31
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	684.49
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	94.76
	Adjustments for provisions, non-current	-53.9
	Adjustments for other financial liabilities, current	77.01
	Adjustments for other financial liabilities, non-current	-14.31
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	6849.27
	Adjustments for interest income	290.39
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	-294.8
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	-4.72
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	**-4800.5**
	Net cash flows from (used in) operations	**3986.53**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	1382.17
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	**2604.36**
3	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	19782.15
	Other cash payments to acquire equity or debt instruments of other entities	21441.75
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	4.82
	Purchase of property, plant and equipment	39.62
	Proceeds from sales of investment property	0
	Purchase of investment property	742.76
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0

	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	6849.27
	Interest received	290.39
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-48.03
	Net cash flows from (used in) investing activities	**4654.47**
4	**Cash flows from used in financing activities**	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	1063.85
	Payments of lease liabilities	0
	Dividends paid	6117.23
	Interest paid	70.37
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	**-7251.45**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**7.38**
5	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**7.38**
	Cash and cash equivalents cash flow statement at beginning of period	109.9
	Cash and cash equivalents cash flow statement at end of period	**117.28**

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

															Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
1	Alembic Limited	AABCA7950P	Alchemy City West Club House Management Association	AAYCA9944L	Other Related party	Sale of goods or services		0.69	No additional remarks			0.29	0	0											
2	Alembic Limited	AABCA7950P	Alchemy City West Club House Management Association	AAYCA9944L	Other Related party	Any other transaction	Reimbursement of Expenses Paid	8.22	No additional remarks			8.22	0	0											
3	Alembic Limited	AABCA7950P	Alchemy City West Club House Management Association	AAYCA9944L	Other Related party	Any other transaction	Security Deposit Received	0	No additional remarks			0	0.12	0.12											There were no transaction during the period.
4	Alembic Limited	AABCA7950P	ALCHEMY CITY WEST PROJECT MANAGEMENT ASSOCIATION	AAYCA4394E	Other Related party	Sale of goods or services		0.69	No additional remarks			0.28	0	0											
5	Alembic Limited	AABCA7950P	ALCHEMY CITY WEST PROJECT MANAGEMENT ASSOCIATION	AAYCA4394E	Other Related party	Any other transaction	Security Deposit Received	0	No additional remarks			0	0.12	0.12											There were no transaction during the period.
6	Alembic Limited	AABCA7950P	Alembic City Limited	AABCA9411F	Subsidiary	Sale of goods or services		8378	No additional remarks			2186.36	0	0											
7	Alembic Limited	AABCA7950P	Alembic City Limited	AABCA9411F	Subsidiary	Any other transaction	Reimbursement of Expenses Paid	236	No additional remarks			18.41	0	0											
8	Alembic Limited	AABCA7950P	Alembic City Limited	AABCA9411F	Subsidiary	Any other transaction	Reimbursement of Expenses Received	944	No additional remarks			281.86	0	0											
9	Alembic Limited	AABCA7950P	Alembic City Limited	AABCA9411F	Subsidiary	Any other transaction	Security Deposit Received	200.87	No additional remarks			200.87	804.14	784.81											
10	Alembic Limited	AABCA7950P	Alembic City Limited	AABCA9411F	Subsidiary	Investment		0	No additional remarks			0	10.07	10.07					Investment	0.00%	NA	Unsecured	NA	There were no transaction during the period
11	Alembic Limited	AABCA7950P	Alembic CSR Foundation	AAETA7647M	Other Related party	Any other transaction	CSR contribution	146.68	No additional remarks			73.22	0	0											
12	Alembic Limited	AABCA7950P	Alembic Limited Provident Fund	AABTT1558R	Other Related party	Any other transaction	Post Employment Benefit Plans	121.47	No additional remarks			121.47	0	0											
13	Alembic Limited	AABCA7950P	Alembic Pharmaceuticals Limited	AAICA5591M	Associate	Sale of goods or services		7846	No additional remarks			2264.15	437.37	194.97											
14	Alembic Limited	AABCA7950P	Alembic Pharmaceuticals Limited	AAICA5591M	Associate	Purchase of goods or services		236	No additional remarks			4.45	0	0.53											
15	Alembic Limited	AABCA7950P	Alembic Pharmaceuticals Limited	AAICA5591M	Associate	Any other transaction	Reimbursement of Expenses Received	700	No additional remarks			217.19	0	0											
16	Alembic Limited	AABCA7950P	Alembic Pharmaceuticals Limited	AAICA5591M	Associate	Any other transaction	Security Deposit Received	0	No additional remarks			0	397.29	397.29											There were no transaction during the period
17	Alembic Limited	AABCA7950P	Alembic Pharmaceuticals Limited	AAICA5591M	Associate	Investment		0	No additional remarks			0	8665.07	8665.07					Investment	0.00%	NA	Unsecured	NA	There were no transaction during the period
18	Alembic Limited	AABCA7950P	Alembic Pharmaceuticals Limited	AAICA5591M	Associate	Dividend received		6731.71	No additional remarks			6731.71	0	0											
19	Alembic Limited	AABCA7950P	Barkha Pranav Amin	AFKPA3430P	Promoter Group	Sale of goods or services		244.46	No additional remarks			244.46	0.27	0											
20	Alembic Limited	AABCA7950P	Bhailal Amin General Hospital	AAATB1585B	Promoter Group	Sale of goods or services		12.86	No additional remarks			5.32	0	0											
21	Alembic Limited	AABCA7950P	Bhailal Amin General Hospital	AAATB1585B	Promoter Group	Any other transaction	Reimbursement of Expenses Received	0.53	No additional remarks			0.53	0	0											
22	Alembic Limited	AABCA7950P	Bhailal Amin General Hospital	AAATB1585B	Promoter Group	Any other transaction	Security Deposit Received	0	No additional remarks			0	2.22	2.22											There were no transaction during the period
23	Alembic Limited	AABCA7950P	Nirayu Private Limited	AAACN7427K	Holding	Sale of goods or services		0.69	No additional remarks			0.28	0	0											

24	Alembic Limited	AABCA7950P	Nirayu Private Limited	AAACN7427K	Holding	Any other transaction	Security Deposit Received	0	No additional remarks			0	0.12	0.12										There were no transaction during the period
25	Alembic Limited	AABCA7950P	Paushak Limited	AAACD5006G	Promoter Group	Sale of goods or services		797.2	No additional remarks			44.78	0	0										
26	Alembic Limited	AABCA7950P	Paushak Limited	AAACD5006G	Promoter Group	Sale of fixed assets		5.69	No additional remarks			5.69	0	0										
27	Alembic Limited	AABCA7950P	Paushak Limited	AAACD5006G	Promoter Group	Purchase of goods or services		177	No additional remarks			3.78	0	0										
28	Alembic Limited	AABCA7950P	Paushak Limited	AAACD5006G	Promoter Group	Dividend received		117.56	No additional remarks			117.56	0	0										
29	Alembic Limited	AABCA7950P	Paushak Limited	AAACD5006G	Promoter Group	Investment		0	No additional remarks			0	16251.74	31167.98					Investment	0.00%	NA	Unsecured	Na	1.There are no transactions during the period. 2.Change in opening and closing values reflects variation in market price (net of necessary tax adjustments) of shares of the listed entity.
30	Alembic Limited	AABCA7950P	Shreno Engineering Limited	ABGCS4837F	Promoter Group	Sale of goods or services		0.69	No additional remarks			0.28	0	0										
31	Alembic Limited	AABCA7950P	Shreno Engineering Limited	ABGCS4837F	Promoter Group	Any other transaction	Security Deposit Received	0	No additional remarks			0	0.12	0.12										There were no transaction during the period
32	Alembic Limited	AABCA7950P	Shreno Limited	AABCA7953Q	Promoter Group	Any other transaction	Reimbursement of Expenses Received	1000	No additional remarks			335.51	51.05	58.8										
33	Alembic Limited	AABCA7950P	Shreno Publications Limited	AAFCA4386B	Promoter Group	Sale of goods or services		105.85	No additional remarks			52.92	0	0										
34	Alembic Limited	AABCA7950P	Chirayu Amin	ABMPA5729P	Key management personnel	Any other transaction	Director's Sitting Fees	1	No additional remarks			1	0	0										
35	Alembic Limited	AABCA7950P	Malika Amin	ABMPA5730G	Promoter	Any other transaction	Director's Sitting Fees	1.2	No additional remarks			1.2	0	0										
36	Alembic Limited	AABCA7950P	Udit Amin	ACKPA4056E	Promoter	Any other transaction	Commission	1000	No additional remarks			450	0	0										
37	Alembic City Limited	AABCA9411F	Alembic Pharmacueticals Limited	AAICA5591M	Promoter Group	Investment		0	No additional remarks			0	0.66	0.83					Investment	0.00%	NA	Unsecured	NA	There were no transactions during the period.
38	Alembic City Limited	AABCA9411F	Alembic Pharmacueticals Limited	AAICA5591M	Promoter Group	Sale of goods or services		82.79	No additional remarks			82.79	0	0										The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
39	Alembic City Limited	AABCA9411F	Alembic Pharmacueticals Limited	AAICA5591M	Promoter Group	Any other transaction	Reimbursement of Expenses Received	12.2	No additional remarks			12.2	0	0										The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
40	Alembic City Limited	AABCA9411F	Alembic Pharmacueticals Limited	AAICA5591M	Promoter Group	Any other transaction	Security Deposit Received	12.04	No additional remarks			12.04	32.44	397.29										
41	Alembic City Limited	AABCA9411F	Paushak Limited	AAACD5006G	Promoter Group	Sale of goods or services		9.75	No additional remarks			9.75	0	0										The transaction does not require approval of Audit committee of

																								the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
42	Alembic City Limited	AABCA9411F	Paushak Limited	AAACD5006G	Promoter Group	Any other transaction	Reimbursement of Expenses Received	3.85	No additional remarks			3.85	0	0										The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
43	Alembic City Limited	AABCA9411F	Paushak Limited	AAACD5006G	Promoter Group	Any other transaction	Security Deposit Received	0	No additional remarks			0	4.13	4.13										There were no transactions during the period.
44	Alembic City Limited	AABCA9411F	Paushak Limited	AAACD5006G	Promoter Group	Investment		0	No additional remarks			0	0.28	0.53					Investment	0.00%	NA	Unsecured	NA	1. There were no transaction during the oeriod 2. Changes in the Opening and Closing value reflects variation in Market Price (Net of necessary Tax Adjustments) of shares of the listed entity.
45	Alembic City Limited	AABCA9411F	Shreno Engineering Limited	ABGCS4837F	Promoter Group	Sale of fixed assets		10.33	No additional remarks			10.33	0	0										
46	Alembic City Limited	AABCA9411F	Shreno Engineering Limited	ABGCS4837F	Promoter Group	Any other transaction	Reimbursement of Expenses Received	1.48	No additional remarks			1.48	0	0										
47	Alembic City Limited	AABCA9411F	Shreno Engineering Limited	ABGCS4837F	Promoter Group	Any other transaction	Security Deposit Received	0	No additional remarks			0	4.38	0.12										There were no transactions during the period.
48	Alembic City Limited	AABCA9411F	Nirayu Private Limited	AAACN7427K	Promoter Group	Any other transaction	Security Deposit Received	0	No additional remarks			0	0	0.12										There were no transactions during the period.
Total value of transaction during the reporting period												13504.23												